Die vorliegende Erfindung betrifft ein erfindungsgemäßes transdermales therapeutisches System (TTS) umfassend Rotigotin und ein pharmazeutisch akzeptables Klebemittel umfassend Styrol-Butadien-Block-Copolymer, eine erfindungsgemäße Matrix mit verzögerter Wirkstofffreisetzung von Rotigotin geeignet für ein TTS, ein erfindungsgemäßes Herstellverfahren für eine entsprechende Matrix oder ein entsprechendes TTS umfassend Rotigotin, sowie Verwendungen der erfindungsgemäßen Matrix sowie des erfindungsgemäßen TTS.Transdermal therapeutic system comprises: (i) a backing layer, (ii) a matrix layer comprising rotigotine, and (iii) a protection film, to be removed before use, which is applied to at least part of the surface of the matrix layer. The matrix layer is applied to at least part of the surface of the backing layer. The matrix layer further comprises an adhesive which is a styrene-butadiene block copolymer, and optionally at least one excipient. Independent claims are also included for: (1) a matrix for sustained release of rotigotine, adhesive comprising styrene-butadiene block copolymer, and optionally at least one additional excipient (2) manufacturing the matrix for sustained-release of rotigotine comprising providing rotigotine, providing the adhesive comprising styrene-butadiene block copolymer, optionally providing excipients, and preparing matrix by mixing the components provided in previous with at least one solvent and (3) producing a transdermal therapeutic system comprising providing rotigotine, providing the adhesive comprising styrene-butadiene block copolymer, optionally providing at least one excipient, preparing matrix by mixing the components provided in previous with at least one solvent, providing a protective film, and producing a two-layer active substance-containing laminate by coating at least a portion of the matrix to at least a part of the protective film, optionally subsequently drying the two-layer active substance-containing laminate under
